Proteasome 20S subunit beta 9 (PSMB9) (PSMB9)

The Immunoproteasome β1i subunit, formally known as Proteasome 20S subunit beta 9 (PSMB9) or LMP2, is a catalytic component of the immunoproteasome, a specialized proteolytic complex induced by proinflammatory cytokines such as interferon-gamma [1, 2]. It replaces the constitutive β1 subunit during assembly, altering the proteasome's catalytic profile to favor the production of peptides with hydrophobic C-termini, which are essential for high-affinity binding to MHC class I molecules [3, 10]. This process is critical for effective antigen presentation and the activation of CD8+ T cells [4, 8]. Beyond antigen processing, β1i plays a significant role in regulating inflammatory cytokine production, T cell differentiation, and maintaining proteostasis under conditions of oxidative stress [5, 7]. Dysregulation or deficiency of this subunit has been implicated in the pathogenesis of autoimmune diseases, chronic inflammation, and specific cancers, such as uterine leiomyosarcoma [5, 16]. Consequently, β1i is a key therapeutic target; selective inhibitors like zetomipzomib (KZR-616) and UK-101 are being developed to treat autoimmune disorders by modulating immune responses while avoiding the broad toxicity of pan-proteasome inhibitors [6, 11, 13]. These inhibitors work by binding to the active site of the subunit, thereby disrupting the generation of immunogenic epitopes and dampening the inflammatory cascade [6, 12]. PSMB9 also serves as a potential biomarker for prognosis and response to immunotherapy in various cancers [15].

Other names

LMP2β1iPSMB6iRING12Low molecular mass protein 2Macropain chain 7Multicatalytic endopeptidase complex chain 7Proteasome subunit beta type-9

Selective inhibition of the β1i subunit of the immunoproteasome, which modulates the generation of MHC class I-restricted peptides and suppresses proinflammatory cytokine signaling.